Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

About this update from Quanterix Corporation

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/a0257b77159aeb22272b8412e869ceb2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FCiDXGKrOjZmSy2sMFPSLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a0257b77159aeb22272b8412e869ceb2","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/aScCHrVJvyJerDtUEpq8tQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a0257b77159aeb22272b8412e869ceb2","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Simoa® technology highlighted in more than 80 posters and oral presentations demonstrating its impact on neurodegenerative disease research","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"BILLERICA, Mass., April 01, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria. This new extraction kit enables researchers to measure low-concentration biomarkers from dried blood spots using a more cost-effective and less invasive method.","length":596,"tagName":"p"},{"type":"text","content":"Current Alzheimer’s and neurodegenerative disease tests often require complex sample handling, repeated collections, and offer limited accessibility, particularly in remote or resource-limited settings, due to their reliance on venous blood draws. To address this, Quanterix, leveraging research from its collaboration with the DROP-AD Project at the University of Gothenburg, has developed a downstream DBS extraction kit that includes buffers and a sample preparation protocol, enabling accurate and sensitive measurement of neuro biomarkers from a DBS matrix. Validation studies show that DBS samples from two different devices tested with Simoa ALZpath p-Tau 217 and the Simoa extraction kit demonstrated correlation to venous in simulated CSF spiked samples of ...

More updates from Quanterix Corporation